| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 7 | | | |
| | | | 11 | | | |
| | | | 12 | | | |
| | | | 12 | | | |
| | | | 19 | | | |
| | | | 38 | | | |
| | | | 39 | | | |
| | | | 42 | | | |
| | | | 43 | | | |
| | | | 48 | | | |
| | | | 51 | | | |
| | | | 58 | | | |
| | | | 58 | | | |
| | | | 60 | | | |
| | | | 67 | | | |
| | | | 68 | | | |
| | | | 69 | | | |
| | | | 70 | | | |
| | | | 71 | | | |
| | | | 72 | | | |
| | | | 81 | | | |
| | | | 82 | | | |
| | | | 85 | | | |
| | | | 85 | | | |
| | | | 85 | | | |
| | | | A-1 | | | |
| | | | B-1 | | |
Proposal
|
| |
Vote
Required |
| |
Broker
Discretionary Voting Allowed |
| |||
Election of Directors
|
| |
Majority of
Votes Cast |
| | | | No | | |
Ratification of KPMG
|
| |
Majority of
Votes Cast |
| | | | Yes | | |
Amendment and Restatement of our 2008 Stock Incentive Plan
|
| |
Majority of
Votes Cast |
| | | | No | | |
Advisory Approval of Executive Compensation (non-binding)
|
| |
Majority of
Votes Cast |
| | | | No | | |
Stockholder Proposal (non-binding)
|
| |
Majority of
Votes Cast |
| | | | No | | |
Name
|
| |
Age(1)
|
| |
Position
|
| |||
Robert J. Hugin
|
| | | | 60 | | | |
Chairman of the Board and Chief Executive Officer
|
|
Richard W. Barker, D.Phil.
|
| | | | 66 | | | |
Director
|
|
Michael W. Bonney
|
| | | | 56 | | | |
Director
|
|
Michael D. Casey
|
| | | | 69 | | | |
Director
|
|
Carrie S. Cox
|
| | | | 57 | | | |
Director
|
|
Michael A. Friedman, M.D.
|
| | | | 71 | | | |
Director
|
|
Gilla Kaplan, Ph.D.
|
| | | | 68 | | | |
Director
|
|
James J. Loughlin
|
| | | | 72 | | | |
Director
|
|
Ernest Mario, Ph.D.
|
| | | | 77 | | | |
Director
|
|
Name and Address of Beneficial Ownership
|
| |
Amount and Nature of
Beneficial Ownership |
| |
Percent
of Class |
| ||||||
Robert J. Hugin
|
| | | | 3,840,755(1) | | | | | | * | | |
Peter N. Kellogg
|
| | | | 132,173(2) | | | | | | * | | |
Mark J. Alles
|
| | | | 351,994(3) | | | | | | * | | |
Thomas O. Daniel, M.D.
|
| | | | 415,242(4) | | | | | | * | | |
Jacqualyn A. Fouse, Ph.D.
|
| | | | 725,511(5) | | | | | | * | | |
Perry A. Karsen
|
| | | | 334,962(6) | | | | | | * | | |
Scott A. Smith
|
| | | | 239,113(7) | | | | | | * | | |
Richard W. Barker, D.Phil.
|
| | | | 88,157(8) | | | | | | * | | |
Michael W. Bonney
|
| | | | 10,000(9) | | | | | | * | | |
Michael D. Casey
|
| | | | 365,335(10) | | | | | | * | | |
Carrie S. Cox
|
| | | | 104,480(11) | | | | | | * | | |
Michael A. Friedman, M.D.
|
| | | | 124,349(12) | | | | | | * | | |
Gilla Kaplan, Ph.D.
|
| | | | 322,799(13) | | | | | | * | | |
James J. Loughlin
|
| | | | 238,968(14) | | | | | | * | | |
Ernest Mario, Ph.D.
|
| | | | 220,233(15) | | | | | | * | | |
All directors and executive officers as a group (16 persons)
|
| | | | 7,641,615(1)-(15) | | | | | | * | | |
BlackRock, Inc.
|
| | | | 50,495,857(16) | | | | | | 6.4% | | |
55 East 52nd Street
|
| | | | | | | | |||||
New York, New York 10022
|
| | | | | | | | |||||
The Vanguard Group.
|
| | | | 42,954,327(17) | | | | | | 5.4% | | |
100 Vanguard Blvd.
|
| | | | | | | | |||||
Malvern, PA 19355
|
| | | | | | | |
|
Name
|
| |
Title
|
|
|
Robert J. Hugin
|
| | Chief Executive Officer and Chairman of the Board | |
|
Peter N. Kellogg
|
| | Executive Vice President, Chief Financial Officer | |
|
Mark J. Alles
|
| | President and Chief Operating Officer | |
|
Thomas O. Daniel, M.D.
|
| | President, Research and Early Development | |
|
Jacqualyn A. Fouse, Ph.D.
|
| | President Hematology and Oncology; formerly Executive Vice President and Chief Financial Officer | |
|
Perry A. Karsen
|
| | Chief Executive Officer, Celgene Cellular Therapeutics | |
|
Scott A. Smith
|
| | President, Inflammation & Immunology | |
| |
Financial Performance
Revenue: Adjusted (non-GAAP (generally accepted accounting principles) total revenue of $7.670 billion, an 18% increase year over year. Contributing to this was:
◦
REVLIMID® sales of $4.980 billion, an increase of 16%
◦
ABRAXANE® sales of $848 million, an increase of 31%
◦
POMALYST®/IMNOVID® sales of $680 million
◦
OTEZLA® sales of $70 million
Earnings Per Share (EPS): Adjusted (non-GAAP) diluted EPS of $3.71, a 24% increase year over year (on a stock split-adjusted basis).
These and other 2014 accomplishments are reflected in our above-target score of 109.75% under our annual cash bonus, or Management Incentive Plan (MIP).
For more information, please see the description of non-GAAP financial achievements in “Key 2014 Compensation Actions and Program Highlights — Annual Bonus (MIP) Payout for Fiscal 2014” and Appendix A — Reconciliation of GAAP to Non-GAAP Net Income.
|
| |
| |
Delivering Value to Our Stockholders
Our stock price increased over 32% in fiscal 2014, reflecting our strong financial performance. Our three-year Total Shareholder Return (TSR)* through December 31, 2014 was 254%, which approximates the 75th percentile of our peer group determined by our Compensation Committee. Relative Total Shareholder Return and its role in our pay-for-performance philosophy under our Long-Term Incentive Plan (“LTIP”) are further described in “Highlights of Best Practices of Our Compensation Programs” and “Long-Term Incentives.”
*
Under our LTIP, TSR is calculated as the percent change in our common stock price at the beginning and the end of each performance cycle, calculated as the difference between the average closing price of our common stock in the 30 trading days preceding the commencement of each performance cycle and the average closing price of our common stock in the final 30 trading days of each performance cycle.
|
| |
| AbbVie Inc. | | | Bristol-Myers Squibb Company | |
| Allergan, Inc.* | | | Eli Lilly and Company | |
| Amgen Inc. | | | Forest Laboratories, Inc.** | |
| Baxter International Inc. | | | Gilead Sciences Inc. | |
| Biogen Idec Inc. | | | Valeant Pharmaceuticals International, Inc. | |
|
Compensation Recovery
|
| | |
In the event of an executive’s fraud or misconduct that results in a material negative restatement of our financial statements, with respect to the year to which the restatement applies (excluding any year before January 1, 2013 for our CEO and before January 1, 2014 for our other NEOs) and for any single year prior to the year in which the Company is required to prepare the restatement, we may recoup any or all of the incentive compensation paid to that executive in excess of the amounts that would have been paid to that executive based on the restated results. We may also cancel unvested incentive compensation or require the executive to repay any gains realized by the executive in excess of the amount that would have been paid to that executive based on the restated results.
|
|
|
Risk Mitigation
|
| | |
We proactively review our compensation programs and policies to ensure they are reflective of our philosophy with regard to risk. The plan features below are designed to promote each NEO’s focus on making decisions that promote a responsible and balanced risk profile:
◦
Diversification and balance of short- and long-term rewards
◦
Multiple metrics within each variable pay program that are balanced and weighted so as not to encourage focus on a single metric to the exclusion of others
◦
Maximum payout caps for all variable and performance-based plans
◦
Share ownership requirements for our NEOs
◦
Holding requirements on shares earned under our Long-Term Incentive Plan (LTIP) of at least one year and one day
|
|
| | | | |
◦
One year and one day holding requirement on all vested, earned Performance Stock Units (PSUs), which were introduced in 2015, as described elsewhere in this proxy statement
|
|
|
Share Ownership Requirements
|
| | |
In order to ensure that our NEOs continue to have a significant stake in our long-term performance and to align executives’ compensation to the interest of stockholders, our NEOs have share ownership requirements. As CEO, Mr. Hugin’s share ownership requirement is an amount equal in value to six times his annual base salary. Our guidelines also provide for target stockholdings in an amount equal in value to three times annual base salary for Messrs. Alles, Karsen, Kellogg, and Smith, Dr. Daniel and Ms. Fouse. These guidelines will be satisfied if the NEO holds, by the end of the applicable five-year period, at least the number of shares of our Common Stock equal to the value of the target amount divided by our stock price on the date the NEO becomes subject to the guidelines. Owned shares, vested restricted or deferred stock units, and vested shares held in the NEO’s 401(k) plan account are included in ownership calculations, but stock options are not. With the exception of Mr. Kellogg, who was hired in fiscal 2014, and Mr. Smith, who became subject to ownership requirements in fiscal 2014, our NEOs met and exceeded their stock ownership guidelines ahead of the required time frame.
|
|
|
Holding Periods
|
| | |
In addition to share ownership requirements, there is a holding period on all shares granted to NEOs under the LTIP of at least one year and one day, and a one year and one day holding period on all vested, earned PSUs. These holding periods further align compensation and value delivered to stock performance and long-term value to our stockholders.
|
|
|
No Repricing
|
| | |
Our 2008 Stock Incentive Plan prohibits us from modifying stock options to reduce the exercise price, substituting a new stock option at a lower price for a surrendered stock option or repurchasing stock options if the per share exercise price is less than the fair market value of a share of Common Stock, unless such action is approved by our stockholders.
|
|
|
Securities Trading Policy
|
| | |
We maintain a comprehensive securities trading policy which provides, among other things, that our employees who possess material non-public information regarding us may not disclose, or trade while in possession of, such information or buy or sell our securities during any designated blackout period. Further, the policy prohibits all employees from short-selling our securities, transacting in derivative securities relating to Celgene without prior written consent of our Chief Executive Officer or holding our stock in a margin account or pledging our stock as collateral for a loan without prior approval of an appropriate officer of the Company. Individuals classified as “insiders” (which includes our NEOs) and related persons (as defined in the policy) generally may not buy or sell our securities at any time without prior approval, except under approved Rule 10b5-1 trading plans.
|
|
|
No Golden Parachute Gross-Up Payments
|
| | |
In April 2014, at Mr. Hugin’s suggestion, his employment agreement was amended to eliminate his golden parachute excise tax gross-up provision. Accordingly, none of our NEOs currently have an agreement with the Company whereby we would be obligated to pay a gross-up for excise taxes in excess of parachute payments as defined in Internal Revenue Code (IRC) Section 280G.
|
|
|
Change in Control Double-Trigger
|
| | |
In 2011, we amended our 2008 Stock Incentive Plan to eliminate the “single-trigger” change in control vesting provision for equity awards granted on or after July 1, 2011 and to provide that, unless otherwise determined at grant, such equity awards vest upon an involuntary termination without cause that occurs within two years following a change in control (i.e., a “double trigger”).
|
|
|
Relative Total Stockholder Return (R-TSR)
|
| | |
A portion of each NEOs long-term compensation is based on R-TSR, either through our active LTIP performance cycles or, beginning in fiscal 2015, through PSUs. R-TSR is calculated as the percent change in our stock price at the beginning and the end of a measurement period compared to an identified peer group of companies for the same period, which is then expressed as a percentile. This measure ensures that executive pay realized through long-term compensation is aligned to our stock performance and value delivered to our stockholders as compared to our identified peer group.
|
|
| NEO Compensation Cost Analysis | | | |
To ensure that our compensation programs remain aligned with the interests of our stockholders and to further reinforce a team-based approach to management, we measure our NEOs’ collective compensation in relation to the collective compensation paid to named executive officers of companies within our peer group as an additional data point when making compensation decisions for our NEOs.
|
|
|
Fixed vs. Performance-Based
|
| |
Performance-Based
Short-Term vs. Long-Term |
|
|
|
| |
|
|
|
Fixed compensation includes base salary;
Performance-based compensation includes bonus, LTIP and equity awards. |
| |
Short-term compensation includes annual bonus;
Long-term compensation includes the value of LTIP and equity awards. |
|
Type
|
| | |
General Terms
|
|
Stock Options
|
| | |
•
Granted quarterly, upon hire and once annually, based on achievement of performance objectives and value creation
•
Service-based vesting over four years (25% per year)
•
Ten-year term
•
Subject to recovery
|
|
Restricted Stock Units (RSUs)
|
| | |
•
Granted annually with the possibility of a subsequent grant on achievement of performance objectives and value creation
•
Service-based cliff vesting (100% vested on third anniversary of grant date)
•
Subject to recovery
|
|
Type
|
| | |
General Terms
|
|
LTIP
|
| | |
•
LTIP awards can be paid in cash, restricted shares of our Common Stock or a combination thereof, as determined by the Compensation Committee
•
If shares are awarded at the conclusion of a three-year performance cycle, they are based on attainment of performance metrics, weighted as follows:
◦
Adjusted Revenue (37.5% weighting)
◦
Adjusted Earnings Per Share (37.5% weighting)
◦
R-TSR (25% weighting)
•
All earned shares are subject to holding periods of at least one year and one day
•
Subject to recovery
•
Commencing in 2015, NEOs no longer participate in new LTIP performance cycles
|
|
Performance Stock Units (PSUs)
|
| | |
•
Granted annually, commencing with the 2015 grant
•
Three-year vesting and measurement period, subject to attainment of defined, weighted metrics established by the Compensation Committee prior to the grant (see Equity Award Mix — 2015 for details)
•
Maximum award is 200% of target
•
All earned PSUs must be held for one year and one day from the vesting date
•
Subject to recovery
|
|
General Provisions for Death, Disability, Termination and Retirement for Stock Options, RSUs and PSUs
|
| | |
•
In the event of death, permanent disability or termination within two years as a result of a change in control (double-trigger), the vesting of stock options, RSUs and PSUs will accelerate
•
If the NEO attains retirement as defined in the 2008 Stock Incentive Plan and has given at least six months’ notice of the intent to retire, as of the date of retirement:
◦
RSUs granted on or after April 29, 2013 will vest on retirement, but will be payable on the earliest of death, disability or the originally scheduled vesting date following retirement (except with respect to our CEO, whose equity awards will immediately vest and become payable in accordance with his employment agreement)
◦
Unvested RSUs granted prior to April 29, 2013 cancel upon retirement unless a prior arrangement has been approved by the Compensation Committee
◦
PSUs will continue to vest and a pro rata portion (based on number of completed months of employment during the vesting period) will be payable based on achievement of defined performance metrics on the earliest of death, disability or the originally scheduled vesting date following retirement (except with respect to our CEO, whose equity awards will immediately vest and become payable in accordance with his employment agreement)
◦
Stock options will continue to vest and will remain exercisable until the earlier of three years after retirement or the original expiration date (except with respect to our CEO, whose equity awards will immediately vest in accordance with his employment agreement)
|
|
Award & Year
|
| |
Measurements & Weights
|
| |
Threshold, Target & Maximum
of Financial Measures |
| |
Peer Group
|
| |||
PSU 2015
|
| |
Adjusted Revenue
|
| |
37.5%
|
| |
90% – 100% – 110%
|
| |
S&P 500 Biotechnology & Pharmaceutical Index Companies
|
|
| | | Adjusted EPS | | |
37.5%
|
| |
90% – 100% – 110%
|
| |||
| | | R-TSR | | |
25%
|
| |
35th – 50th – 80th
(percentiles) |
|
| | |
Performance Stock Unit
Awards |
| |||||||||||||||
Name
|
| |
Threshold
(50% of target) |
| |
Target
|
| |
Maximum
(200% of target) |
| |||||||||
Robert J. Hugin
|
| | | | 14,700 | | | | | | 29,400 | | | | | | 58,800 | | |
Peter N. Kellogg
|
| | | | 3,100 | | | | | | 6,200 | | | | | | 12,400 | | |
Mark Alles
|
| | | | 3,100 | | | | | | 6,200 | | | | | | 12,400 | | |
Thomas Daniel
|
| | | | 3,100 | | | | | | 6,200 | | | | | | 12,400 | | |
Jacqualyn Fouse
|
| | | | 3,100 | | | | | | 6,200 | | | | | | 12,400 | | |
Perry A. Karsen
|
| | | | 3,100 | | | | | | 6,200 | | | | | | 12,400 | | |
Scott A. Smith
|
| | | | 3,100 | | | | | | 6,200 | | | | | | 12,400 | | |
Performance Cycle
|
| |
Measurements & Weights
|
| |
Threshold, Target & Maximum
of Financial Measures |
| |
Peer Group
|
| |||
2013–2015
|
| |
Adjusted Revenue
|
| |
37.5%
|
| |
90% – 100% – 125%
|
| |
Top 35
biopharmaceutical peers according to market capitalization prior to the commencement of the performance cycle |
|
| | | Adjusted EPS | | |
37.5%
|
| |
90% – 100% – 125%
|
| |||
| | | R-TSR | | |
25%
|
| |
50th – 70th – 90th
(percentiles) |
| |||
2014–2016
|
| |
Adjusted Revenue
|
| |
37.5%
|
| |
90% – 100% – 110%
|
| |
Top 35
biopharmaceutical peers according to market capitalization prior to the commencement of the performance cycle |
|
| | | Adjusted EPS | | |
37.5%
|
| |
90% – 100% – 110%
|
| |||
| | | R-TSR | | |
25%
|
| |
35th – 50th – 80th
(percentiles) |
|
Name
|
| |
2013 Salary
|
| |
2014 Salary
|
| |
Effective Date of
Salary Adjustment(1) |
| |
2015 Salary
|
| |
Effective Date of
Salary Adjustment |
| |||||||||||||||
Robert J. Hugin
|
| | | $ | 1,280,000 | | | | | $ | 1,400,000 | | | | | | 3/1/2014 | | | | | $ | 1,500,000 | | | | | | 3/1/2015 | | |
Peter Kellogg
|
| | | $ | — | | | | | $ | 800,000 | | | | | | 7/1/2014 | | | | | $ | 824,000 | | | | | | 3/1/2015 | | |
Mark J. Alles
|
| | | $ | 670,000 | | | | | $ | 850,000 | | | | | | 8/1/2014 | | | | | $ | 875,500 | | | | | | 3/1/2015 | | |
Thomas O. Daniel, M.D.
|
| | | $ | 649,000 | | | | | $ | 700,000 | | | | | | 3/1/2014 | | | | | $ | 721,000 | | | | | | 3/1/2015 | | |
Jacqualyn A. Fouse, Ph.D.
|
| | | $ | 757,000 | | | | | $ | 825,000 | | | | | | 8/1/2014 | | | | | $ | 849,800 | | | | | | 3/1/2015 | | |
Perry A. Karsen
|
| | | $ | 649,000 | | | | | $ | 670,000 | | | | | | 3/1/2014 | | | | | $ | 690,100 | | | | | | 3/1/2015 | | |
Scott A. Smith
|
| | | $ | 490,000 | | | | | $ | 600,000 | | | | | | 8/1/2014 | | | | | $ | 650,000 | | | | | | 3/1/2015 | | |
NEO
|
| |
Bonus
Target for Fiscal 2014(1) |
| |
Corporate
Weighting X Corporate Score |
| |
Other Weighting
X Other Score |
| |
Bonus Paid
2/27/2015 |
| |
2015
Target |
| |||||||||
Robert J. Hugin
|
| | | | 150% | | | |
100% x 109.75%
|
| |
—
|
| | | $ | 2,271,825 | | | | | | 150% | | |
Peter Kellogg
|
| | | | 70% | | | |
—
|
| |
—
|
| | | $ | 560,000(2) | | | | | | 70% | | |
Mark J. Alles
|
| | | | 79% | | | |
100% x 109.75%
|
| |
—
|
| | | $ | 667,692 | | | | | | 90% | | |
Thomas O. Daniel, M.D.
|
| | | | 70% | | | |
100% x 109.75%
|
| |
—
|
| | | $ | 531,245 | | | | | | 70% | | |
Jacqualyn A. Fouse, Ph.D.
|
| | | | 74% | | | |
100% x 109.75%
|
| |
—
|
| | | $ | 654,823 | | | | | | 80% | | |
Perry A. Karsen
|
| | | | 70% | | | |
100% x 109.75%
|
| |
—
|
| | | $ | 512,039 | | | | | | 70% | | |
Scott A. Smith
|
| | | | 61% | | | |
20% x 109.75%
|
| |
80% x 120.4%
|
| | | $ | 396,941(3) | | | | | | 75% | | |
Name
|
| |
Stock Options(1)
|
| |
RSUs(2)
|
|||||
Robert J. Hugin
|
| | | | 356,000(3) | | | | | | 44,500(4) |
Peter N. Kellogg
|
| | | | 121,935(5)(8) | | | | | | 65,510(5)(8) |
Mark J. Alles
|
| | | | 69,845(6)(8) | | | | | | 8,750(7)(8) |
Thomas O. Daniel, M.D.
|
| | | | 65,935(6)(8) | | | | | | 7,610(7)(8) |
Jacqualyn A. Fouse, Ph.D.
|
| | | | 69,845(6)(8) | | | | | | 8,750(7)(8) |
Perry A. Karsen
|
| | | | 69,845(6)(8) | | | | | | 4,200(7) |
Scott A. Smith
|
| | | | 36,760(9) | | | | | | 8,410(9) |
Name
|
| |
Threshold(1)(4)
|
| |
Target(2)(4)
|
| |
Maximum(3)(4)
|
| |||||||||
Robert J. Hugin
|
| | | $ | 587,500 | | | | | $ | 1,468,750 | | | | | $ | 2,350,000 | | |
| | | 14,888 shares | | | | | | 37,222 shares | | | | | | 59,554 shares | | | ||
Peter N. Kellogg
|
| | | $ | 200,000 | | | | | $ | 400,000 | | | | | $ | 800,000 | | |
| | | 2,493 shares | | | | | | 4,986 shares | | | | | | 9,973 shares | | | ||
Mark J. Alles
|
| | | $ | 325,000 | | | | | $ | 650,000 | | | | | $ | 1,300,000 | | |
| | | 8,236 shares | | | | | | 16,472 shares | | | | | | 32,944 shares | | | ||
Thomas O. Daniel, M.D.
|
| | | $ | 315,000 | | | | | $ | 630,000 | | | | | $ | 1,260,000 | | |
| | | 7,982 shares | | | | | | 15,966 shares | | | | | | 31,932 shares | | | ||
Jacqualyn A. Fouse, Ph.D.
|
| | | $ | 367,500 | | | | | $ | 735,000 | | | | | $ | 1,470,000 | | |
| | | 9,314 shares | | | | | | 18,626 shares | | | | | | 37,252 shares | | | ||
Perry A. Karsen
|
| | | $ | 315,000 | | | | | $ | 630,000 | | | | | $ | 1,260,000 | | |
| | | 7,982 shares | | | | | | 15,966 shares | | | | | | 31,932 shares | | | ||
Scott A. Smith
|
| | | $ | 118,750 | | | | | $ | 237,500 | | | | | $ | 475,000 | | |
Name
|
| |
Threshold(1)(4)
|
| |
Target(2)(4)
|
| |
Maximum(3)(4)
|
| |||||||||
Robert J. Hugin
|
| | | $ | 640,000 | | | | | $ | 1,600,000 | | | | | $ | 2,560,000 | | |
| | | 7,810 shares | | | | | | 19,526 shares | | | | | | 31,240 shares | | | ||
Peter N. Kellogg
|
| | | $ | 333,333 | | | | | $ | 666,667 | | | | | $ | 1,333,333 | | |
| | | 4,155 shares | | | | | | 8,310 shares | | | | | | 16,621 shares | | | ||
Mark J. Alles
|
| | | $ | 335,000 | | | | | $ | 670,000 | | | | | $ | 1,340,000 | | |
| | | 4,088 shares | | | | | | 8,176 shares | | | | | | 16,352 shares | | | ||
Thomas O. Daniel, M.D.
|
| | | $ | 324,500 | | | | | $ | 649,000 | | | | | $ | 1,298,000 | | |
| | | 3,960 shares | | | | | | 7,920 shares | | | | | | 15,840 shares | | | ||
Jacqualyn A. Fouse, Ph.D.
|
| | | $ | 378,500 | | | | | $ | 757,000 | | | | | $ | 1,514,000 | | |
| | | 4,618 shares | | | | | | 9,238 shares | | | | | | 18,476 shares | | | ||
Perry A. Karsen
|
| | | $ | 324,500 | | | | | $ | 649,000 | | | | | $ | 1,298,000 | | |
| | | 3,960 shares | | | | | | 7,920 shares | | | | | | 15,840 shares | | | ||
Scott A. Smith
|
| | | $ | 122,500 | | | | | $ | 245,000 | | | | | $ | 490,000 | | |
Name
|
| |
Matching Contributions under the 401(k) Plan(1)
|
|
Robert J. Hugin
|
| | 177.97299 shares of Common Stock (fair value of $19,908) | |
Peter Kellogg
|
| | 62.74696 shares of Common Stock (fair value of $7,019) | |
Mark J. Alles
|
| | 177.97299 shares of Common Stock (fair value of $19,908) | |
Thomas O. Daniel, M.D
|
| | 177.97299 shares of Common Stock (fair value of $19,908) | |
Jacqualyn A. Fouse, Ph.D.
|
| | 177.97299 shares of Common Stock (fair value of $19,908) | |
Perry A. Karsen
|
| | 177.97299 shares of Common Stock (fair value of $19,908) | |
Scott A. Smith
|
| | 177.97299 shares of Common Stock (fair value of $19,908) | |
Name
|
| |
Age(1)
|
| |
Position
|
| |||
Robert J. Hugin
|
| | | | 60 | | | | Chief Executive Officer and Chairman of the Board | |
Peter N. Kellogg
|
| | | | 59 | | | | Executive Vice President and Chief Financial Officer | |
Mark J. Alles
|
| | | | 56 | | | | President and Chief Operating Officer | |
Thomas O. Daniel, M.D.
|
| | | | 61 | | | | President, Research and Early Development | |
Jacqualyn A. Fouse, Ph.D.
|
| | | | 54 | | | | President Hematology and Oncology; formerly Executive Vice President and Chief Financial Officer |
|
Perry A. Karsen
|
| | | | 60 | | | | Chief Executive Officer of Celgene Cellular Therapeutics | |
Scott A. Smith
|
| | | | 53 | | | | President, Inflammation & Immunology | |
Lawrence V. Stein
|
| | | | 65 | | | |
Executive Vice President, General Counsel and Corporate Secretary
|
|
Name and Principal Position
|
| |
Year
|
| |
Salary
|
| |
Bonus(1)
|
| |
Stock
Awards(2) |
| |
Option
Awards(2) |
| |
Non-Equity
Incentive Plan Compensation(3) |
| |
Change in
Pension Value and Nonqualified Deferred Compensation Earnings(4) |
| |
All Other
Compensation(5) |
| |
Total
|
| ||||||||||||||||||||||||
(a)
|
| |
(b)
|
| |
(c)
|
| |
(d)
|
| |
(e)
|
| |
(f)
|
| |
(g)
|
| |
(h)
|
| |
(i)
|
| |
(j)
|
| ||||||||||||||||||||||||
Robert J. Hugin
Chief Executive Officer and Chairman of the Board(6) |
| |
2014
|
| | | $ | 1,380,000 | | | | | | — | | | | | $ | 3,899,980 | | | | | $ | 9,614,448 | | | | | $ | 9,110,269 | | | | | | — | | | | | $ | 231,416 | | | | | $ | 24,236,113 | | |
|
2013
|
| | | $ | 1,262,500 | | | | | | — | | | | | $ | 3,554,100 | | | | | $ | 8,729,638 | | | | | $ | 7,236,693 | | | | | | — | | | | | $ | 212,854 | | | | | $ | 20,995,785 | | | ||
|
2012
|
| | | $ | 1,158,333 | | | | | | — | | | | | $ | 2,333,760 | | | | | $ | 3,658,941 | | | | | $ | 3,229,303 | | | | | | — | | | | | $ | 193,685 | | | | | $ | 10,574,022 | | | ||
Peter N. Kellogg
Executive Vice President and Chief Financial Officer(7) |
| |
2014
|
| | | $ | 400,000 | | | | | | — | | | | | $ | 5,815,094 | | | | | $ | 3,313,252 | | | | | $ | 560,000 | | | | | | — | | | | | $ | 9,098 | | | | | $ | 10,097,444 | | |
Mark J. Alles
President and Chief Operating Officer |
| |
2014
|
| | | $ | 767,917 | | | | | | — | | | | | $ | 901,257 | | | | | $ | 2,077,620 | | | | | $ | 4,278,167 | | | | | | — | | | | | $ | 21,272 | | | | | $ | 8,046,233 | | |
|
2013
|
| | | $ | 666,667 | | | | | | — | | | | | $ | 1,186,586 | | | | | $ | 2,440,484 | | | | | $ | 3,188,449 | | | | | | — | | | | | $ | 20,511 | | | | | $ | 7,502,697 | | | ||
|
2012
|
| | | $ | 641,667 | | | | | | — | | | | | $ | 1,185,800 | | | | | $ | 1,088,350 | | | | | $ | 770,988 | | | | | | — | | | | | $ | 18,285 | | | | | $ | 3,705,090 | | | ||
Thomas O. Daniel, M.D.
President, Research and Early Development |
| |
2014
|
| | | $ | 691,500 | | | | | | — | | | | | $ | 767,672 | | | | | $ | 1,921,324 | | | | | $ | 4,141,720 | | | | | | — | | | | | $ | 148,364 | | | | | $ | 7,670,580 | | |
|
2013
|
| | | $ | 645,833 | | | | | | — | | | | | $ | 1,059,360 | | | | | $ | 2,269,123 | | | | | $ | 3,165,006 | | | | | | — | | | | | $ | 100,434 | | | | | $ | 7,239,756 | | | ||
|
2012
|
| | | $ | 625,000 | | | | | | — | | | | | $ | 1,018,083 | | | | | $ | 957,823 | | | | | $ | 859,993 | | | | | | — | | | | | $ | 97,685 | | | | | $ | 3,558,584 | | | ||
Jacqualyn A. Fouse, Ph.D.
President Hematology and Oncology(7) |
| |
2014
|
| | | $ | 803,250 | | | | | | — | | | | | $ | 901,257 | | | | | $ | 2,077,620 | | | | | $ | 4,867,123 | | | | | | — | | | | | $ | 22,238 | | | | | $ | 8,671,488 | | |
|
2013
|
| | | $ | 753,333 | | | | | | — | | | | | $ | 1,059,360 | | | | | $ | 2,269,123 | | | | | $ | 3,692,296 | | | | | | — | | | | | $ | 21,829 | | | | | $ | 7,795,941 | | | ||
|
2012
|
| | | $ | 729,167 | | | | | | — | | | | | $ | 1,018,083 | | | | | $ | 1,178,617 | | | | | $ | 505,951 | | | | | | — | | | | | $ | 18,285 | | | | | $ | 3,450,103 | | | ||
Perry A. Karsen
Chief Executive Officer, CCT |
| |
2014
|
| | | $ | 666,500 | | | | | | — | | | | | $ | 368,088 | | | | | $ | 2,077,620 | | | | | $ | 4,122,514 | | | | | | — | | | | | $ | 24,440 | | | | | $ | 7,259,162 | | |
|
2013
|
| | | $ | 645,833 | | | | | | — | | | | | $ | 1,008,796 | | | | | $ | 2,200,579 | | | | | $ | 3,165,006 | | | | | | — | | | | | $ | 31,129 | | | | | $ | 7,051,343 | | | ||
|
2012
|
| | | $ | 625,000 | | | | | | — | | | | | $ | 1,018,083 | | | | | $ | 957,823 | | | | | $ | 1,224,969 | | | | | | — | | | | | $ | 18,285 | | | | | $ | 3,844,160 | | | ||
Scott A. Smith
President, I&I |
| |
2014
|
| | | $ | 546,246 | | | | | | — | | | | | $ | 837,784 | | | | | $ | 1,141,664 | | | | | $ | 719,941 | | | | | | — | | | | | $ | 22,238 | | | | | $ | 3,267,873 | | |
Name
|
| |
Year
|
| |
Value of
Employer Contributions to the Nonqualified Plan* |
| |
Value of
Matching Contributions To the 401(k) Plan in Shares of Common Stock** |
| |
Professional
Tax and Financial Counseling |
| |
Excess
Liability Insurance Premiums |
| |
Contributions
to Health Savings Account |
| |
Other***
|
| |
Total
|
| |||||||||||||||||||||
Robert J. Hugin
|
| |
2014
|
| | | $ | 207,000 | | | | | $ | 19,908 | | | | | | — | | | | | $ | 2,330 | | | | | $ | 2,178 | | | | | | — | | | | | $ | 231,416 | | |
|
2013
|
| | | $ | 189,375 | | | | | $ | 19,597 | | | | | | — | | | | | $ | 2,232 | | | | | $ | 1,650 | | | | | | — | | | | | $ | 212,854 | | | ||
|
2012
|
| | | $ | 173,750 | | | | | $ | 16,064 | | | | | | — | | | | | $ | 2,221 | | | | | $ | 1,650 | | | | | | — | | | | | $ | 193,685 | | | ||
Peter Kellogg
|
| |
2014
|
| | | | — | | | | | $ | 7,019 | | | | | $ | 2,079 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 9,098 | | |
Mark J. Alles
|
| |
2014
|
| | | | — | | | | | $ | 19,908 | | | | | | — | | | | | $ | 1,364 | | | | | | — | | | | | | — | | | | | $ | 21,272 | | |
|
2013
|
| | | | — | | | | | $ | 19,597 | | | | | | — | | | | | $ | 914 | | | | | | — | | | | | | — | | | | | $ | 20,511 | | | ||
|
2012
|
| | | | — | | | | | $ | 16,064 | | | | | | — | | | | | $ | 2,221 | | | | | | — | | | | | | — | | | | | $ | 18,285 | | | ||
Thomas O. Daniel, M.D.
|
| |
2014
|
| | | | — | | | | | $ | 19,908 | | | | | | — | | | | | $ | 518 | | | | | | — | | | | | $ | 127,938 | | | | | $ | 148,364 | | |
|
2013
|
| | | | — | | | | | $ | 19,597 | | | | | | — | | | | | $ | 2,232 | | | | | | — | | | | | $ | 78,605 | | | | | $ | 100,434 | | | ||
|
2012
|
| | | | — | | | | | $ | 16,064 | | | | | | — | | | | | $ | 2,221 | | | | | | — | | | | | $ | 79,400 | | | | | $ | 97,685 | | | ||
Jacqualyn A. Fouse, Ph.D.
|
| |
2014
|
| | | | — | | | | | $ | 19,908 | | | | | | — | | | | | $ | 2,330 | | | | | | — | | | | | | — | | | | | $ | 22,238 | | |
|
2013
|
| | | | — | | | | | $ | 19,597 | | | | | | — | | | | | $ | 2,232 | | | | | | — | | | | | | — | | | | | $ | 21,829 | | | ||
|
2012
|
| | | | — | | | | | $ | 16,064 | | | | | | — | | | | | $ | 2,221 | | | | | | — | | | | | | — | | | | | $ | 18,285 | | | ||
Perry A. Karsen
|
| |
2014
|
| | | | — | | | | | $ | 19,908 | | | | | $ | 2,202 | | | | | $ | 2,330 | | | | | | — | | | | | | — | | | | | $ | 24,440 | | |
|
2013
|
| | | | — | | | | | $ | 19,597 | | | | | $ | 9,300 | | | | | $ | 2,232 | | | | | | — | | | | | | — | | | | | $ | 31,129 | | | ||
|
2012
|
| | | | — | | | | | $ | 16,064 | | | | | | — | | | | | $ | 2,221 | | | | | | — | | | | | | — | | | | | $ | 18,285 | | | ||
Scott A. Smith
|
| |
2014
|
| | | | — | | | | | $ | 19,908 | | | | | | — | | | | | $ | 2,330 | | | | | | — | | | | | | — | | | | | $ | 22,238 | | |
Name
|
| |
Grant
Date |
| |
Comm
Action(1) |
| |
Estimated Potential/Future
Payouts Under Non-Equity Incentive Plan Awards(2)(3) |
| |
Stock
Awards Number of Shares of Stock or Units(4) |
| |
Awards
Number of Securities Underlying Options (#)(4) |
| |
Exercise
or Base Price of Option Awards ($/Sh)(5) |
| |
Grant
Date Fair Value of Stock and Options(6) |
| |||||||||||||||||||||||||||||||||
|
Threshold
|
| |
Target
|
| |
Maximum
|
| |||||||||||||||||||||||||||||||||||||||||||||||
(a)
|
| |
(b)
|
| | | | | | | |
(c)
|
| |
(d)
|
| |
(e)
|
| |
(i)
|
| |
(j)
|
| |
(k)
|
| |
(l)
|
| ||||||||||||||||||||||||
Robert J. Hugin
|
| | | | | | | | | | 12/11/2013(2) | | | | | $ | 640,000 | | | | | $ | 1,600,000 | | | | | $ | 2,560,000 | | | | | | | ||||||||||||||||||||
| | | | | | | | | 2/11/2014(3) | | | | | $ | — | | | | | $ | 2,070,000 | | | | | $ | 4,140,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | ||
| | | 2/3/2014 | | | | | | 2/12/2013 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 117,500 | | | | | $ | 74.30 | | | | | $ | 3,011,472 | | | ||
| | | 7/28/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 159,000 | | | | | $ | 87.64 | | | | | $ | 3,974,396 | | | ||
| | | 7/28/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | 44,500 | | | | | | — | | | | | $ | 87.64 | | | | | $ | 3,899,980 | | | ||
| | | 10/27/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 79,500 | | | | | $ | 103.10 | | | | | $ | 2,628,580 | | | ||
| | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||
Peter N. Kellogg
|
| | | | | | | | | | 5/13/2014 | | | | | $ | 333,333 | | | | | $ | 666,667 | | | | | $ | 1,333,333 | | | | | | | ||||||||||||||||||||
| | | | | | | | | 5/13/2014 | | | | | $ | — | | | | | $ | 560,000 | | | | | $ | 560,000 | | | | | | | ||||||||||||||||||||||
| | | 8/1/2014 | | | | | | 5/13/2014 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 100,000 | | | | | $ | 86.65 | | | | | $ | 2,506,740 | | | ||
| | | 8/1/2014 | | | | | | 5/13/2014 | | | | | | | | | | | | | | | | | | | | | | | | 60,000 | | | | | | — | | | | | $ | 86.65 | | | | | $ | 5,199,000 | | | ||
| | | 10/27/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 10,175 | | | | | $ | 103.10 | | | | | $ | 336,425 | | | ||
| | | 10/27/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | 2,100 | | | | | | — | | | | | $ | 103.10 | | | | | $ | 216,510 | | | ||
| | | 12/19/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 11,760 | | | | | $ | 117.18 | | | | | $ | 470,087 | | | ||
| | | 12/19/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | 3,410 | | | | | | — | | | | | $ | 117.18 | | | | | $ | 399,584 | | | ||
| | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||
Mark J. Alles
|
| | | | | | | | | | 12/11/2013(2) | | | | | $ | 335,000 | | | | | $ | 670,000 | | | | | $ | 1,340,000 | | | | | | | ||||||||||||||||||||
| | | | | | | | | 2/11/2014(3) | | | | | $ | — | | | | | $ | 608,375 | | | | | $ | 1,216,750 | | | | | | | ||||||||||||||||||||||
| | | 2/3/2014 | | | | | | 2/12/2013 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 23,650 | | | | | $ | 74.30 | | | | | $ | 606,139 | | | ||
| | | 7/28/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 20,350 | | | | | $ | 87.64 | | | | | $ | 508,673 | | | ||
| | | 7/28/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | 4,200 | | | | | | — | | | | | $ | 87.64 | | | | | $ | 368,088 | | | ||
| | | 10/27/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 10,175 | | | | | $ | 103.10 | | | | | $ | 336,425 | | | ||
| | | 12/19/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 15,670 | | | | | $ | 117.18 | | | | | $ | 626,383 | | | ||
| | | 12/19/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | 4,550 | | | | | | — | | | | | $ | 117.18 | | | | | $ | 533,169 | | | ||
| | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||
Thomas O. Daniel, M.D.
|
| | | | | | | | | | 12/11/2013(2) | | | | | $ | 324,500 | | | | | $ | 649,000 | | | | | $ | 1,298,000 | | | | | | | ||||||||||||||||||||
| | | | | | | | | 2/11/2014(3) | | | | | $ | — | | | | | $ | 484,050 | | | | | $ | 968,100 | | | | | | | ||||||||||||||||||||||
| | | 2/3/2014 | | | | | | 2/12/2013 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 23,650 | | | | | $ | 74.30 | | | | | $ | 606,139 | | | ||
| | | 7/28/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 20,350 | | | | | $ | 87.64 | | | | | $ | 508,673 | | | ||
| | | 7/28/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | 4,200 | | | | | | — | | | | | $ | 87.64 | | | | | $ | 368,088 | | | ||
| | | 10/27/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 10,175 | | | | | $ | 103.10 | | | | | $ | 336,425 | | | ||
| | | 12/19/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 11,760 | | | | | $ | 117.18 | | | | | $ | 470,087 | | | ||
| | | 12/19/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | 3,410 | | | | | | — | | | | | $ | 117.18 | | | | | $ | 399,584 | | |
Name
|
| |
Grant
Date |
| |
Comm
Action(1) |
| |
Estimated Potential/Future
Payouts Under Non-Equity Incentive Plan Awards(2)(3) |
| |
Stock
Awards Number of Shares of Stock or Units(4) |
| |
Awards
Number of Securities Underlying Options (#)(4) |
| |
Exercise
or Base Price of Option Awards ($/Sh)(5) |
| |
Grant
Date Fair Value of Stock and Options(6) |
| |||||||||||||||||||||||||||||||||
|
Threshold
|
| |
Target
|
| |
Maximum
|
| |||||||||||||||||||||||||||||||||||||||||||||||
(a)
|
| |
(b)
|
| | | | | | | |
(c)
|
| |
(d)
|
| |
(e)
|
| |
(i)
|
| |
(j)
|
| |
(k)
|
| |
(l)
|
| ||||||||||||||||||||||||
Jacqualyn A. Fouse, Ph.D.
|
| | | | | | | | | | 12/11/2013(2) | | | | | $ | 378,500 | | | | | $ | 757,000 | | | | | $ | 1,514,000 | | | | | | | ||||||||||||||||||||
| | | | | | | | | 2/11/2014(3) | | | | | $ | — | | | | | $ | 596,650 | | | | | $ | 1,193,300 | | | | | | | ||||||||||||||||||||||
| | | 2/3/2014 | | | | | | 2/12/2013 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 23,650 | | | | | $ | 74.30 | | | | | $ | 606,139 | | | ||
| | | 7/28/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 20,350 | | | | | $ | 87.64 | | | | | $ | 508,673 | | | ||
| | | 7/28/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | 4,200 | | | | | | — | | | | | $ | 87.64 | | | | | $ | 368,088 | | | ||
| | | 10/27/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 10,175 | | | | | $ | 103.10 | | | | | $ | 336,425 | | | ||
| | | 12/19/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 15,670 | | | | | $ | 117.18 | | | | | $ | 626,383 | | | ||
| | | 12/19/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | 4,550 | | | | | | — | | | | | $ | 117.18 | | | | | $ | 533,169 | | | ||
| | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||
Perry A. Karsen
|
| | | | | | | | | | 12/11/2013(2) | | | | | $ | 324,500 | | | | | $ | 649,000 | | | | | $ | 1,298,000 | | | | | | | ||||||||||||||||||||
| | | | | | | | | 2/11/2014(3) | | | | | $ | — | | | | | $ | 466,550 | | | | | $ | 933,100 | | | | | | | ||||||||||||||||||||||
| | | 2/3/2014 | | | | | | 2/12/2013 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 23,650 | | | | | $ | 74.30 | | | | | $ | 606,139 | | | ||
| | | 7/28/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 20,350 | | | | | $ | 87.64 | | | | | $ | 508,673 | | | ||
| | | 7/28/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | 4,200 | | | | | | — | | | | | $ | 87.64 | | | | | $ | 368,088 | | | ||
| | | 10/27/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 10,175 | | | | | $ | 103.10 | | | | | $ | 336,425 | | | ||
| | | 12/19/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 15,670 | | | | | $ | 117.18 | | | | | $ | 626,383 | | | ||
| | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||
Scott A. Smith
|
| | | | | | | | | | 12/11/2013(2) | | | | | $ | 122,500 | | | | | $ | 245,000 | | | | | $ | 490,000 | | | | | | | ||||||||||||||||||||
| | | | | | | | | 2/11/2014(3) | | | | | $ | — | | | | | $ | 335,623 | | | | | $ | 671,246 | | | | | | | ||||||||||||||||||||||
| | | 2/3/2014 | | | | | | 2/12/2013 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 10,000 | | | | | $ | 74.30 | | | | | $ | 256,296 | | | ||
| | | 7/28/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 10,000 | | | | | $ | 87.64 | | | | | $ | 249,962 | | | ||
| | | 7/28/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | 5,000 | | | | | | — | | | | | $ | 87.64 | | | | | $ | 438,200 | | | ||
| | | 10/27/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 5,000 | | | | | $ | 103.10 | | | | | $ | 165,320 | | | ||
| | | 12/19/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 11,760 | | | | | $ | 117.18 | | | | | $ | 470,087 | | | ||
| | | 12/19/2014 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | 3,410 | | | | | | — | | | | | $ | 117.18 | | | | | $ | 399,584 | | |
| | |
Option Awards
|
| |
Stock Awards
|
| |||||||||||||||||||||||||||||||||||||||
Name
|
| |
Number of
Securities Underlying Unexercised Options (#) Exercisable(1) |
| |
Number of
Securities Underlying Unexercised Options (#) Unexercisable(2) |
| |
Equity
Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) |
| |
Option
Exercise Price |
| |
Option
Expiration Date |
| |
Number
of Shares or Units of Stock That Have Not Vested (#)(3) |
| |
Market
Value of Shares or Units of Stock That Have Not Vested ($)(4) |
| |
Equity
Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) |
| |
Equity
Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) |
| ||||||||||||||||||
(a)
|
| |
(b)
|
| |
(c)
|
| |
(d)
|
| |
(e)
|
| |
(f)
|
| |
(g)
|
| |
(h)
|
| |
(i)
|